"name","studyEstimands","documentVersion","description","studyDesignRationale","id","label","bcCategories","uuid:ID","studyInvestigationalInterventions"
"Study Design 1","[]","","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","","[]","7db12b29-0f5a-4848-b74c-660a804d68e2","[]"
